The Cancer SIGNAL

Dr. Eric Klein, Distinguished Scientist at GRAIL, provides a research update from GRAIL’s 2024 findings on multi-cancer early detection (MCED) testing, presented at ASCO, ESMO, AACR and more. He explores insights from the first real-world evaluation of repeat multi-cancer early detection testing, data on how multi-cancer early detection (MCED) testing is helping cancer survivors

At their doctor’s recommendation, Rich and Staci each took a multi-cancer early detection test during a routine checkup. Despite having no symptoms, Rich received a Cancer Signal Detected result, while Staci, who had a strong family history of cancer, did not. Listen to their story and learn about the impact of early cancer detection. Watch the full episode on YouTube: https://yo

Seven in 10 Americans are behind on at least one routine cancer screening. Jody Hoyos, CEO of the Prevent Cancer Foundation, joins Susanna to discuss the critical role of early cancer detection. She addresses the most common misconceptions about cancer screening and explains the importance of proactive screening, even when no symptoms are present. Help shape future episodes by ta

Introducing our new host, Susanna Quinn! Susanna is a cancer survivor, entrepreneur, writer and philanthropist. Diagnosed with stage three ovarian cancer in 2019, Susanna underwent aggressive treatment and achieved cancer-free status by September of the same year. In this episode, Kim Thiboldeaux, the Cancer SIGNAL’s inaugural host, interviews Susanna about her cancer story and p

Dr. Scout, Executive Director of the National LGBT Cancer Network, discusses how the LGBTQ+ community faces unique challenges in cancer screening. Dr. Scout highlights the increased cancer risks due to social factors, like discrimination and medical mistrust, and emphasizes the importance of inclusive healthcare provider training. The National LGBT Cancer Network works to educate b

Jon Rendina and Dwight Venson of Whitman-Walker, a healthcare center historically focused on the LGBTQ+ community, join us to delve into how LGBTQ+ people and people of color face disparities in cancer incidence. Whitman-Walker, Cancer Support Community, and GRAIL are collaborating on INCLUDE, a study to evaluate multi-cancer early detection (MCED) testing’s impact within federal

Diverse clinical trials provide more meaningful data to researchers, but too many trials are based around monolithic audience groups. In early disease detection, particularly in conditions like cancer, diversity in clinical trials is especially important. Our guests, Eucharia Borden of the cancer nonprofit Family Reach and Dr. Gary Puckrein of the National Minority Quality Forum, d

After supporting her husband through his shocking cancer experience, Cindy decided to take a multi-cancer early detection test as recommended by her doctor. She was once again shocked when she received a “cancer signal detected” result, leading to a cancer diagnosis. Join us to hear about Cindy’s experience with early detection, treatment, and eventual remission, and what she

Join host Kim Thiboldeaux and Krissa Smith, VP of Mission Partnerships at Susan G. Komen, as they continue unraveling how the BRCA gene and other DNA mutations impact hereditary cancer risk. In this episode, Krissa shares personal stories about her family's experiences with genetic testing and how they’ve chosen to respond. Krissa also discusses cancer screening best practices an

Krissa Smith, Vice President of Mission Partnerships at Susan G. Komen, joins us to discuss the complexities of the BRCA gene and its impact on hereditary cancer risk. Krissa shares her family's experiences with genetic mutations, including the p53 gene, and explains the importance of genetic testing and how it can work in partnership with evolving cancer screening technology. Stay